OTCMKTS:CHGCY Chugai Pharmaceutical (CHGCY) Stock Price, News & Analysis $19.08 -0.25 (-1.29%) As of 10/2/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsInsider TradesNews and TrendsShort Interest About Chugai Pharmaceutical Stock (OTCMKTS:CHGCY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Chugai Pharmaceutical alerts:Sign Up Key Stats Today's Range$19.00▼$19.8950-Day Range$19.08▼$22.6252-Week Range$19.00▼$34.84Volume794,244 shsAverage Volume280,012 shsMarket Capitalization$62.80 billionP/E Ratio20.74Dividend Yield1.31%Price TargetN/AConsensus RatingModerate Buy Company Overview Chugai Pharmaceutical Co., Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its research focuses on oncology, immunology, neuroscience, hematology and other areas of significant unmet medical need, with capabilities spanning drug discovery, clinical development, manufacturing and commercialization. Chugai’s portfolio includes medicines such as Actemra (tocilizumab), an immunology treatment; Hemlibra (emicizumab), used to prevent bleeding in people with hemophilia A; and Alecensa (alectinib), a targeted therapy for certain forms of lung cancer. The company also develops antibody-based therapies and other biologic and small-molecule medicines. Founded in 1925 and headquartered in Tokyo, Chugai operates primarily in Japan while serving international markets through its global business and strategic relationship with Roche. Chugai and Roche have maintained a strategic alliance since 2002, under which Roche distributes certain Chugai-developed products internationally and Chugai markets selected Roche products in Japan. Chugai is listed in Japan, and its American depositary shares trade over the counter under the symbol CHGCY.AI Generated. May Contain Errors. Read More Chugai Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreCHGCY MarketRank™: Chugai Pharmaceutical scored higher than 61% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingModerate Buy Consensus RatingChugai Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 strong buy rating, 1 buy rating, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageChugai Pharmaceutical has only been the subject of 2 research reports in the past 90 days.Read more about Chugai Pharmaceutical's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth28.13% Earnings GrowthEarnings for Chugai Pharmaceutical are expected to grow by 28.13% in the coming year, from $0.96 to $1.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chugai Pharmaceutical is 20.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.66.Price to Earnings Ratio vs. SectorThe P/E ratio of Chugai Pharmaceutical is 20.74, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.67.Price to Book Value per Share RatioChugai Pharmaceutical has a P/B Ratio of 4.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Chugai Pharmaceutical's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Chugai Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverChugai Pharmaceutical has a short interest ratio ("days to cover") of 0.09, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chugai Pharmaceutical has recently increased by 90.03%, indicating that investor sentiment is decreasing significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldChugai Pharmaceutical pays a meaningful dividend of 1.29%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthChugai Pharmaceutical does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Chugai Pharmaceutical is 27.17%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Chugai Pharmaceutical will have a dividend payout ratio of 20.33% next year. This indicates that Chugai Pharmaceutical will be able to sustain or increase its dividend.Read more about Chugai Pharmaceutical's dividend. News and Social Media2.5 / 5News Sentiment0.06 News SentimentChugai Pharmaceutical has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Chugai Pharmaceutical this week, compared to 0 articles on an average week.Search Interest4 people have searched for CHGCY on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Chugai Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by Institutions0.01% of the stock of Chugai Pharmaceutical is held by institutions.Read more about Chugai Pharmaceutical's insider trading history. Receive CHGCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chugai Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CHGCY Stock News HeadlinesChugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down - What's Next?October 1 at 6:41 AM | americanbankingnews.comChugai Pharmaceutical (OTCMKTS:CHGCY) Reaches New 12-Month Low - Time to Sell?September 28, 2026 | americanbankingnews.comFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that. | Stansberry Research (Ad)Chugai Pharmaceutical Co. Ltd. ADRAugust 19, 2026 | wsj.comChugai Pharmaceutical Co., Ltd. (CHGCY) Q2 2026 Earnings Call TranscriptJuly 24, 2026 | seekingalpha.comChugai Pharmaceutical Co., Ltd. (CHGCY) Q4 2025 Earnings Call TranscriptJanuary 29, 2026 | seekingalpha.comChugai Reports Positive Data From TEIEN Study Of Port Delivery System With Ranibizumab In NAMD & DMENovember 25, 2025 | finanznachrichten.deChugai Pharmaceutical to Merge with Renalys Pharma to Boost Kidney Disease Drug DevelopmentNovember 18, 2025 | msn.comSee More Headlines CHGCY Stock Analysis - Frequently Asked Questions How have CHGCY shares performed this year? Chugai Pharmaceutical's stock was trading at $26.27 at the beginning of the year. Since then, CHGCY shares have decreased by 27.4% and is now trading at $19.08. How were Chugai Pharmaceutical's earnings last quarter? Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) posted its earnings results on Friday, July, 24th. The company reported $0.22 earnings per share for the quarter. The business had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.38 billion. Chugai Pharmaceutical had a trailing twelve-month return on equity of 23.76% and a net margin of 35.09%. How do I buy shares of Chugai Pharmaceutical? Shares of CHGCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings7/24/2026Today10/03/2026Next Earnings (Estimated)10/23/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:CHGCY CIK1453934 Webwww.chugai-pharm.co.jp Phone(133) 281-6611FaxN/AEmployees7,872Year Founded1925Profitability EPS (Trailing Twelve Months)$0.92 Trailing P/E Ratio20.74 Forward P/E Ratio19.88 P/E GrowthN/ANet Income$2.91 billion Net Margins35.09% Pretax MarginN/A Return on Equity23.76% Return on Assets19.92% Debt Debt-to-Equity RatioN/A Current Ratio4.35 Quick Ratio3.54 Sales & Book Value Annual Sales$8.41 billion Price / Sales7.46 Cash Flow$0.95 per share Price / Cash Flow20.12 Book Value$4.12 per share Price / Book4.63Miscellaneous Outstanding Shares3,291,430,000Free FloatN/AMarket Cap$62.80 billion OptionableNot Optionable Beta0.60 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (OTCMKTS:CHGCY) was last updated on 10/4/2026 by MarketBeat.com Staff. From Our PartnersLarry's Three-Step Strategy Revealed at The Dollar Trap SummitLarry unveiled a three-step strategy at last night's Dollar Trap Summit, with no options, futures, or cryptocu...Brownstone Research | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredA major gold reset could be closer than people thinkFor 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One...Reagan Gold Group | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...Stansberry Research | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chugai Pharmaceutical Co., Ltd. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Chugai Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CHGCY Stock Alerts